Zürich/Los Angeles Der Schweizer Pharmakonzern Novartis bietet Krankenversicherungen in den USA Preisnachlässe für seine neue Gentherapie gegen die Muskelerkrankung SMA.
LOS ANGELES/ZURICH Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached.
Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.
May 2 Gilead Sciences Inc on Thursday
reported a higher first-quarter profit as sales of its important
HIV and hepatitis C drugs were largely in line with Wall Street
Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.
April 30 Amgen Inc on Tuesday reported
first-quarter revenue that was unchanged from a year ago and net
income fell 14 percent as sales of key drugs, including new
migraine treatment Aimovig and cholesterol fighter Repatha, face
competition and pressure to lower prices.
The U.S. Centers for Medicare and Medicaid Services will slightly increase coverage for expensive CAR-T cell therapies administered at certain large hospitals, and is considering other ways to pay more for the cancer treatments, the agency said on Tuesday.
Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.
Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.
NEW YORK/LOS ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.